Sensei Biotherapeutics to Participate in Oppenheimer’s 33rd Annual Healthcare Conference

Rhea-AI Summary

Sensei Biotherapeutics (Nasdaq: SNSE) is set to present at Oppenheimer’s 33rd Annual Healthcare Conference on March 13, 2023. The presentation will begin at 8:00 a.m. ET and be accessible via a webcast on the company’s website. The webcast replay will be available for around 90 days after the event.

Sensei Biotherapeutics focuses on developing next-generation immuno-oncology therapeutics for cancer treatment, with its lead candidate being SNS-101, designed to target the VISTA checkpoint within tumor microenvironments. The company also works on candidates SNS-102 and SNS-103, aimed at different immunosuppressive signals.

BOSTON, March 06, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that Company management will present at Oppenheimer’s 33^rd Annual Healthcare Conference. The presentation will be available at 8:00 a.m. ET on Monday, March 13^th, 2023.

A webcast of Sensei’s presentation will be available in the Investors section of the Sensei website. A replay of the webcast will be on the website for approximately 90 days following the event. Registration for the webcast is available here.

About Sensei Biotherapeutics
Sensei Biotherapeutics (NASDAQ: SNSE) is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb™ (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable checkpoints and other immunosuppressive signals selectively in the tumor microenvironment to unleash T cells against tumors. Sensei’s lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. The company is also developing SNS-102, a conditional binding monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4), as well as SNS-103, also a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), also known as CD39. For more information, please visit www.senseibio.com, and follow the company on Twitter @SenseiBio and LinkedIn.

Investor Contact:
Michael Biega
Senior Director, Investor Relations
Sensei Biotherapeutics
mbiega@senseibio.com

Media Contact:
Chris Railey
Ten Bridge Communications
chris@tenbridgecommunications.com

FAQ

What is the date and time of Sensei Biotherapeutics' presentation at the Oppenheimer Healthcare Conference?

Sensei Biotherapeutics will present on March 13, 2023, at 8:00 a.m. ET.

How can I access the webcast of Sensei Biotherapeutics' presentation?

The webcast will be available on Sensei Biotherapeutics' website in the Investors section.

What is Sensei Biotherapeutics' main focus in the healthcare sector?

Sensei Biotherapeutics specializes in developing next-generation therapeutics for cancer patients, specifically in immuno-oncology.

What is the lead investigational candidate of Sensei Biotherapeutics?

The lead investigational candidate is SNS-101, aimed at blocking the VISTA checkpoint in the tumor microenvironment.

What additional candidates is Sensei Biotherapeutics developing?

The company is also working on SNS-102 and SNS-103, targeting other immunosuppressive signals.